QA/RA Consulting, Auditing & Training
Menu
QA/RA Consulting, Auditing & Training
Since QMSR enforcement began on February 2, 2026, FDA inspections are already revealing how the agency intends to apply this new framework – not just in the first few months, but as inspection consistency matures.
The observations below reflect early QMSR enforcement results, drawn from publicly available FDA inspection data, FDA‑hosted town halls, and our experience supporting manufacturers through QMSR‑based inspections and remediation activities. While enforcement will continue to evolve, these early patterns provide meaningful insight into how FDA is interpreting ISO 13485 within its regulatory authority and what manufacturers should expect during future inspections.
FDA has confirmed that full enforcement of the QMSR began on February 2, 2026, with inspections conducted under the new Compliance Program 7382.850 – not QSIT. There has been no grace period beyond the two year transition that ended on the enforcement date.
However, early enforcement actions (483s and warning letters) include what FDA itself has described as “transitional language.” In practice, investigators are documenting one or more of the following:
This confirms that FDA is intentionally signaling how deficiencies map under the new framework rather than treating QMSR gaps as brand-new violations.
For inspections that were completed under the QSR, instructions given in warning letters issued after QMSR implementation indicate that company responses should follow the latter (QMSR) requirements.
This is one of the most concrete changes seen in actual enforcement. FDA inspection data released and discussed at the FDA QMSR Town Hall meeting held on April 1, 2026 shows:
FDA has confirmed (and inspectors are demonstrating) that:
Importantly, FDA has stated that ISO 13485 certification alone does not insulate a firm from FDA enforcement, even if the same records were recently reviewed by a Notified Body (or auditing organization).
Based on compiled Form 483 data and FDA commentary, early QMSR enforcement is clustering around:
FDA has begun issuing warning letters under QMSR; however, early activity indicates that enforcement escalation is being staged rather than accelerated. FDA has consistently emphasized the need for inspection consistency and investigator proficiency as QMSR is implemented across the field.
As a result, early enforcement trends should be read as an indicator of how FDA is sequencing enforcement – not a signal that deficiencies are being tolerated. Firms should expect increased consistency and confidence in inspection outcomes as implementation matures, rather than a retreat from enforcement expectations.
The absence of these patterns in early enforcement does not mean they will not emerge, but it provides important context for where FDA has – and has not – focused enforcement attention during initial QMSR implementation. Significantly, there is no evidence so far of:
Early FDA inspections under QMSR confirm that this is not a lighter weight version of QSR. QMSR reflects a more integrated, risk driven regulatory expectation: one that evaluates how well quality system elements function together, not whether required documents exist in isolation.
Manufacturers that have treated ISO 13485 certification as primarily a documentation exercise are already being exposed. FDA inspections are assessing how risk management, design controls, supplier oversight, CAPA, and management review operate as a unified system – and whether leadership can demonstrate effective oversight of that system.
ELIQUENT helps manufacturers respond to FDA’s QMSR inspection approach through:
Reach out to ELIQUENT Life Sciences to learn how we can help you act on these early QMSR enforcement signals.
US Office Washington DC
The European Commission’s proposal is a response to device shortages, innovation flight, and SME attrition, but its deeper intent is stability. Regulators are signaling that predictable manufacturers deserve predictable regulation. Those who internalize this shift will:
Those who treat this as merely a compliance simplification exercise will miss the deeper competitive inflection.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
